局部[177Lu]Lu-RM26放射配体治疗胶质母细胞瘤的抗肿瘤疗效与安全性
该研究基于GRPR在胶质瘤中高表达且与不良预后相关,在GL261Fluc+原位胶质母细胞瘤模型中经对流增强递送局部给予[177Lu]Lu-RM26,观察到肿瘤滞留延长(74.7 h)、吸收剂量高(2.71×10^6 mGy·MBq^-1)、脱靶摄取少,并显著抑制肿瘤生长、延长生存,短期未见明显全身毒性或神经功能损害。
要点
- GRPR高表达与胶质瘤不良预后亚型及生存缩短相关。
- 局部给药实现肿瘤高滞留与高吸收剂量,脱靶摄取少。
- 治疗抑制肿瘤生长并延长生存,短期毒性不明显。
核心结论
- 局部[177Lu]Lu-RM26治疗可实现持续、肿瘤特异性的β辐射且全身暴露极少,是GRPR阳性胶质母细胞瘤有前景的局部治疗策略。
研究设计与样本
- 利用中国胶质瘤基因组图谱和临床试验数据集在转录组和蛋白水平分析GRPR表达及预后相关性。
- 在GL261Fluc+原位胶质母细胞瘤模型中经对流增强递送局部给予[177Lu]Lu-RM26,并以系列SPECT和γ计数评估药代动力学。
主要发现
- GRPR表达较高与预后较差的胶质瘤亚型及生存缩短相关。
- 体外实验显示对GL261Fluc+细胞活力、增殖和侵袭呈剂量依赖性抑制。
- 局部给药后肿瘤滞留时间为74.7 h,吸收剂量为2.71×10^6 mGy·MBq^-1,脱靶摄取极少。
- 治疗小鼠较对照出现明显肿瘤生长抑制、生物发光信号降低和生存延长。
- 未观察到明显短期全身毒性或神经功能损害,转录组和Western blot结果与DNA复制停滞和G2/M期阻滞一致。
关键数值与推荐
- 肿瘤滞留时间为74.7 h,吸收剂量为2.71×10^6 mGy·MBq^-1。
- 未观察到明显短期全身毒性或神经功能损害。
临床怎么用
- 对GRPR阳性胶质母细胞瘤,可考虑经对流增强递送局部给予[177Lu]Lu-RM26以实现肿瘤高剂量照射并减少全身暴露。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Glioblastoma multiforme (GBM) remains an aggressive brain malignancy with dismal prognosis despite current standard-of-care therapies. The gastrin-releasing peptide receptor (GRPR) is overexpressed in gliomas and represents a potential therapeutic target. However, systemic radionuclide delivery is limited by poor tumor penetration and off-target toxicity. METHODS: GRPR expression and prognostic relevance were analyzed using Chinese Glioma Genome Atlas and a clinical-trial dataset, respectively at the transcriptomic and protein levels. [177Lu]Lu-RM26, a lutetium-177-labeled GRPR-targeting antagonist, was evaluated in vitro, and administered intratumorally via convection-enhanced delivery in an orthotopic GL261Fluc+ glioblastoma model. Pharmacokinetic characteristics, including tumor retention and biodistribution, were evaluated by serial single-photon emission computed tomography and gamma-counting. Efficacy was assessed by tumor volume, bioluminescence signal, and overall survival. Safety was evaluated through body weight monitoring, neurological scoring, rotarod testing, hematology, and immunohistochemical staining. Mechanistic insights were obtained via bulk RNA-sequencing and Western blotting. RESULTS: Higher GRPR expression correlated with poorer-prognosis glioma subtypes and reduced survival. In vitro assays showed dose-dependent inhibition of GL261Fluc+ cell viability, proliferation, and invasion. Locoregional [177Lu]Lu-RM26 administration led to prolonged tumor retention (74.7 h), high absorbed dose (2.71 × 106 mGy·MBq- 1), and minimal off-target uptake. Treated mice exhibited marked tumor growth inhibition, reduced bioluminescence signal, and extended survival compared to controls. No significant short-term systemic toxicity or neurological impairment was observed. Transcriptome and Western blotting findings were consistent with DNA replication stalling and G2/M arrest. CONCLUSION: Locoregional [177Lu]Lu-RM26 therapy enables sustained, tumor-specific β-radiation with minimal systemic exposure, representing a promising locoregional strategy for GRPR-positive GBM.
引用
- Wang L, Xiang J, Li L, et al. Antitumor efficacy and safety of locoregional [177Lu]Lu-RM26 radionuclide therapy in glioblastoma. Eur J Nucl Med Mol Imaging. 2026. PMID: 42301422. doi:10.1007/s00259-026-07993-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。